NASDAQ : OBX
Obsidian Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 14.79 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 913.62M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 891.38M |
| Enterprise Value | 859.84M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 61.77M |
| Shares Outstanding | 61.77M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +35,061.25% |
| Owned by Insiders (%) | 2.39% |
| Owned by Institutions (%) | 13.65% |
| Float | 48.85M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 28.76 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.30 |
| Quick Ratio | 1.71 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -311.16% |
| Weighted Average Cost of Capital (WACC) | 18.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.08M |
| Employee Count | 87 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.64 |
| 52-Week Price Change | +87.57% |
| 50-Day Moving Average | 15.18 |
| 200-Day Moving Average | 18.04 |
| Relative Strength Index (RSI) | 51.50 |
| Average Volume (20 Days) | 349,355 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.08M |
| Short Previous Month | 884,528 |
| Short % of Shares Out | 1.75% |
| Short % of Float | 2.21% |
| Short Ratio (days to cover) | 1.60 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -97.23M |
| Pretax Income | -94.22M |
| Net Income | -94.22M |
| EBITDA | -95.86M |
| EBIT | -97.23M |
| Earnings Per Share (EPS) | -$31.84 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 34.45M |
| Total Debt | 2.91M |
| Net Cash | 31.54M |
| Net Cash Per Share | $0.51 |
| Equity (Book Value) | 30.32M |
| Book Value Per Share | -13.51 |
| Working Capital | 26.16M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -91.81M |
| Capital Expenditures | -16,000 |
| Depreciation & Amortization | 1.37M |
| Net Borrowing | n/a |
| Free Cash Flow | -91.83M |
| FCF Per Share | -$1.49 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -220.66% |
| FCF Yield | -10.53% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $39.00 |
| Price Target Difference | 170.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 4, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:1.42 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |